PF 6838435

Drug Profile

PF 6838435

Alternative Names: PF-06838435

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Monoclonal antibodies
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemophilia

Most Recent Events

  • 02 Aug 2016 PF 6838435 receives Breakthrough Therapy status for Haemophilia in USA
  • 18 May 2016 PF 6838435 receives Orphan Drug status for Haemophilia in USA
  • 04 May 2016 Phase-II clinical trials in Haemophilia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top